The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 2, 2011, Pages 1156-1163

  Barber, Alistair J ^a   Gardner, Thomas W ^a,b   Abcouwer, Steven F ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; GELATINASE A; GLUTAMATE AMMONIA LIGASE; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURON SPECIFIC NUCLEAR PROTEIN; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 2;

AMINO ACID TRANSPORT; APOPTOSIS; BASEMENT MEMBRANE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CELL DEATH; CELL LOSS; CELL SURVIVAL; DIABETIC RETINOPATHY; EXCITOTOXICITY; GLUTAMATE TRANSPORT; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MICROGLIA; MICROVASCULAR ENDOTHELIAL CELL; MITOCHONDRION; MUELLER CELL; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PERICYTE; PRIORITY JOURNAL; RETINA; RETINA BLOOD VESSEL; RETINA CELL; RETINA GANGLION CELL; RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; ANIMAL; PATHOLOGY; RETINA NERVE CELL;

ANIMALS; APOPTOSIS; DIABETIC RETINOPATHY; HUMANS; RETINAL NEURONS; RETINAL VESSELS;

EID: 79953269159     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6293     Document Type: Review

References (117)

1. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabet Metabol Rev. 1995;11:109-120.
2. Bresnick GH, Davis MD, Myers FL, de Venecia G. Clinicopathologic correlations in diabetic retinopathy, II: clinical and histologic appearances of retinal capillary microaneurysms. Arch Ophthalmol. 1977;95:1215-1220.
3. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 1996;97:2883-2890.
4. Sugiyama T, Kobayashi M, Kawamura H, Li Q, Puro DG. Enhancement of P2X(7)-induced pore formation and apoptosis: an early effect of diabetes on the retinal microvasculature. Invest Ophthalmol Vis Sci. 2004;45:1026-1032.
5. Kern TS, Tang J, Mizutani M, et al. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci. 2000;41:3972-3978.
6. Joussen AM, Poulaki V, Mitsiades N, et al. Suppression of Fas-FasLinduced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2003;17:76-78.
7. Kowluru RA, Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci. 2004;45:4161-4166.
8. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008; 172:1411-1418.
9. Cheung AK, Fung MK, Lo AC, et al. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apo-ptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005;54:3119-3125.
10. Podesta F, Romeo G, Liu WH, et al. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol. 2000;156:1025-1032.
11. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns, IV: Diabetic retinopathy. Arch Ophthalmol. 1961;66:366-378.
12. Kern TS, Engerman RL. Comparison of retinal lesions in alloxandiabetic rats and galactose-fed rats. Curr Eye Res. 1994;13:863-867.
13. Sima AA, Chakrabarti S, Garcia-Salinas R, Basu PK. The BB-rat-an authentic model of human diabetic retinopathy. Curr Eye Res. 1985;4:1087-1092.
14. Bandopadhyay R, Orte C, Lawrenson JG, Reid AR, De Silva S, Allt G. Contractile proteins in pericytes at the blood-brain and bloodretinal barriers. J Neurocytol. 2001;30:35-44.
15. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998-1003.
16. Moss SE, Klein R, Klein BE. The incidence of vision loss in adiabetic population. Ophthalmology. 1988;95:1340-1348.
17. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV: the long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
18. Cunha-Vaz J, Faria de Abreu JR, Campos AJ. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol. 1975;59: 649-656.
19. Lobo CL, Bernardes RC, Santos FJ, Cunha-Vaz JG. Mapping retinal fluorescein leakage with confocal scanning laser fluorometry of the human vitreous. Arch Ophthalmol. 1999;117:631-637.
20. Jones CW, Cunha-Vaz JG, Rusin MM. Vitreous fluorophotometry in the alloxan- and streptozocin-treated rat. Arch Ophthalmol. 1982;100:1141-1145.
21. Williamson JR, Chang K, Tilton RG, et al. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes: prevention by aldose reductase inhibitors and castration. Diabetes. 1987;36: 813-821.
22. Do Carmo A, Ramos P, Reis A, Proenca R, Cunha-Vaz JG. Breakdown of the inner and outer blood retinal barrier in streptozotocin- induced diabetes. Exp Eye Res. 1998;67:569-575.
23. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest OphthalmolVis Sci. 2003;44:5410-5416.
24. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes. 1998;47:1953-1959.
25. Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med. 1995;1:527-534.
26. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNELpositive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031-1035.
27. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest. 1998;102:783-791.
28. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006; 168:235-244.
29. Kanamori A, Nakamura M, Mukuno H, Maeda H, Negi A. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr Eye Res. 2004;28: 47-54.
30. Barber AJ, Lieth E. Agrin accumulates in the brain microvascular basal lamina during development of the blood-brain barrier. Dev Dyn. 1997;208:62-74.
31. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46:2210-2218.
32. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci. 2004;45:3330-3336.
33. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci. 2008;49:2635-2642.
34. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci. 2006;47:3143-3150.
35. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17:463-471.
36. Scott TM, Foote J, Peat B, Galway G. Vascular and neural changes in the rat optic nerve following induction of diabetes with streptozotocin. J Anat. 1986;144:145-152.
37. Lopes de Faria JM, Russ H, Costa VP. Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol. 2002;86:725-728.
38. Chihara E, Matsuoka T, Ogura Y, Matsumura M. Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. Ophthalmology. 1993;100:1147-1151.
39. van Dijk HW, Kok PHB, Garvin M, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:3404-3409.
40. van Dijk HW, Verbraak FD, Kok PH, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51:3660-3665.
41. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci. 2004;45:2760-2766.
42. Ng JS, Bearse MA Jr, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci. 2008;49:1622-1628.
43. Kim SY, Johnson MA, McLeod DS, et al. Retinopathy in monkeys with spontaneous type 2 diabetes. Invest Ophthalmol Vis Sci. 2004;45:4543-4553.
44. Bloodworth JM Jr. Diabetic retinopathy. Diabetes. 1962;11:1-22.
45. Wolter JR. Diabetic retinopathy. Am J Ophthalmol. 1961;51: 1123-1139.
46. Zorumski CF, Olney JW. Excitotoxic neuronal damage and neuropsychiatric disorders. Pharmacol Ther. 1993;59:145-162.
47. Weiss JH, Sensi SL. Ca2+-Zn2+permeable AMPA or kainatereceptors: possible key factors in selective neurodegeneration. Trends Neurosci. 2000;23:365-371.
48. Ambati J, Chalam KV, Chawla DK, et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115:1161-1166.
49. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes. 1998;47:815-820.
50. Kowluru RA, Engerman RL, Case GL, Kern TS. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int. 2001;38: 385-390.
51. Lieth E, LaNoue KF, Antonetti DA, Ratz M. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. Exp Eye Res. 2000;70:723-730.
52. Hutson SM, Lieth E, LaNoue KF. Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. J Nutr. 2001;131:846S-850S.
53. LaNoue KF, Berkich DA, Conway M, et al. Role of specific aminotransferases in de novo glutamate synthesis and redox shuttling in the retina. J Neurosci Res. 2001;66:914-922.
54. Lieth E, LaNoue KF, Berkich DA, et al. Nitrogen shuttling between neurons and glial cells during glutamate synthesis. J Neurochem. 2001;76:1712-1723.
55. Laabich A, Cooper NG. Neuroprotective effect of AIP on N-methyl- D-aspartate-induced cell death in retinal neurons. Brain Res Mol Brain Res. 2000;85:32-40.
56. Laabich A, Cooper NG. Regulation of calcium/calmodulin-dependent protein kinase II in the adult rat retina is mediated by ionotropic glutamate receptors. Exp Eye Res. 1999;68:703-713.
57. Ward MM, Jobling AI, Kalloniatis M, Fletcher EL. Glutamate uptake in retinal glial cells during diabetes. Diabetologia. 2005;48: 351-360.
58. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci. 2002;43:3109-3116.
59. Puro DG. Diabetes-induced dysfunction of retinal Muller cells.Trans Am Ophthalmol Soc. 2002;100:339-352.
60. Mysona B, Dun Y, Duplantier J, Ganapathy V, Smith SB. Effects of hyperglycemia and oxidative stress on the glutamate transporters GLAST and system xc- in mouse retinal Muller glial cells. Cell Tissue Res. 2009;335:477-488.
61. Santiago AR, Hughes JM, Kamphuis W, Schlingemann RO, Ambrosio AF. Diabetes changes ionotropic glutamate receptor subunit expression level in the human retina. Brain Res. 2008;1198: 153-159.
62. Ng YK, Zeng XX, Ling EA. Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Res. 2004;1018:66-72.
63. Semkova I, Huemmeke M, Ho MS, et al. Retinal localization of the glutamate receptor GluR2 and GluR2-regulating proteins in diabetic rats. Exp Eye Res. 2010;90:244-253.
64. Santiago AR, Rosa SC, Santos PF, Cristovao AJ, Barber AJ, Ambrosio AF. Elevated glucose changes the expression of ionotropic glutamate receptor subunits and impairs calcium homeostasis in retinal neural cells. Invest Ophthalmol Vis Sci. 2006;47:4130-4137.
65. Chakrabarti S, Sima AA, Lee J, Brachet P, Dicou E. Nerve growth factor (NGF), proNGF and NGF receptor-like immunoreactivity in BB rat retina. Brain Res. 1990;523:11-15.
66. Nitta A, Murai R, Suzuki N, et al. Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol Teratol. 2002; 24:695-701.
67. Seki M, Tanaka T, Nawa H, et al. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocininduced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes. 2004;53:2412-2419.
68. Reiter CE, Gardner TW. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Progr Retinal Eye Res. 2003;22:545-562.
69. Reiter CE, Sandirasegarane L, Wolpert EB, et al. Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol Endocrinol Metab. 2003;285:E763-E774.
70. Reiter CE, Wu X, Sandirasegarane L, et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes. 2006;55:1148-1156.
71. Rajala RV, Wiskur B, Tanito M, Callegan M, Rajala A. Diabetes reduces autophosphorylation of retinal insulin receptor and increases protein-tyrosine phosphatase-1B activity. Invest Ophthalmol Vis Sci. 2009;50:1033-1040.
72. Enge M, Bjarnegard M, Gerhardt H, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 2002;21:4307-4316.
73. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009;15:1298-1306.
74. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
75. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl. 2000;77:S26-S30.
76. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003;26:1589-1596.
77. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Med. 2003;9:294-299.
78. Dong QY, Cui Y, Chen L, Song J, Sun L. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. Eur J Ophthalmol. 2008;18:94-98.
79. Wakabayashi Y, Usui Y, Shibauchi Y, Uchino H, Goto H. Increased levels of 8-hydroxydeoxyguanosine in the vitreous of patients with diabetic retinopathy. Diabetes Res Clin Pract. 2010; 89:e59-e61.
80. Kowluru R, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or galactosemia, II: comparison of gammaglutamyl transpeptidase in retina and cerebral cortex, and effects of antioxidant therapy. Curr Eye Res. 1994;13:891-896.
81. Kowluru RA, Kern TS, Engerman RL, Armstrong D. Abnormalities of retinal metabolism in diabetes or experimental galactosemia, III: effects of antioxidants. Diabetes. 1996;45:1233-1237.
82. Kowluru RA, Koppolu P. Diabetes-induced activation of caspase-3 in retina: effect of antioxidant therapy. Free Radic Res. 2002;36:993-999.
83. Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes. 2004;53:3233-3238.
84. Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia. 2010;53:971-979.
85. Arnal E, Miranda M, Johnsen-Soriano S, et al. Beneficial effect ofdocosahexanoic acid and lutein on retinal structural, metabolic, and functional abnormalities in diabetic rats. Curr Eye Res. 2009; 34:928-938.
86. Crispim D, Fagundes NJ, dos Santos KG, et al. Polymorphisms of the UCP2 gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. Clin Endocrinol. 2010; 72:612-619.
87. Cui Y, Xu X, Bi H, et al. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res. 2006;83:807-816.
88. Barnstable CJ. Mitochondria and the regulation of free radical damage in the eye. J Ocul Biol Dis Informatics. 2009;2:145-148.
89. Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunctionin the retina. Invest Ophthalmol Vis Sci. 2003;44:5327-5334.
90. Busik JV, Mohr S, Grant MB. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes. 2008;57:1952-1965.
91. Mohammad G, Kowluru RA. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest. 2010;90:1365-1372.
92. Silva PS, Sun JK, Aiello LP. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24:93-99.
93. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-365.
94. Wakabayashi Y, Usui Y, Okunuki Y, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina. 2010;30:339-344.
95. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Med. 2005;22:719-722.
96. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20: 1366-1369.
97. Brucklacher RM, Patel KM, Vanguilder HD, et al. Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genom. 2008;1:26.
98. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest Ophthalmol Vis Sci. 2005;46:349-357.
99. Zeng HY, Green WR, Tso MO, Zeng H-Y, Green WR, Tso MOM. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126:227-232.
100. Gaucher D, Chiappore J-A, Paques M, et al. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47:612-623.
101. Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41:1971-1980.
102. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005; 54:1559-1565.
103. Mertsch K, Hanisch UK, Kettenmann H, Schnitzer J. Characterization of microglial cells and their response to stimulation in an organotypic retinal culture system. J Comp Neurol. 2001;431: 217-227.
104. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol. 2004;88:1343-1347.
105. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56:224-230.
106. Joussen AM, Doehmen S, Le ML, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vision. 2009;15:1418-1428.
107. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32- week study. Diabetes Care. 2010;33:1523-1528.
108. Fogal B, Hewett SJ. Interleukin-1beta: a bridge between inflammation and excitotoxicity? J Neurochem. 2008;106:1-23.
109. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Progr Brain Res. 2008;173:409-421.
110. Abcouwer SF, Shanmugam S, Gomez PF, et al. Effect of IL-1beta on survival and energy metabolism of R28 and RGC-5 retinal neurons. Invest Ophthalmol Vis Sci. 2008;49:5581-5592.
111. Vanguilder HD, Brucklacher RM, Patel K, Ellis RW, Freeman WM, Barber AJ. Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina. Eur J Neurosci. 2008;28:1-11.
112. Kurihara T, Ozawa Y, Nagai N, et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes. 2008;57: 2191-2198.
113. 2+/calmodulin-dependent protein kinase II activity in diabetic mouse retina. Diabetes. 2010;59: 1825-1835.
114. Sokol S, Moskowitz A, Skarf B, Evans R, Molitch M, Senior B. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol. 1985;103:51-54.
115. Di Leo MA, Caputo S, Falsini B, et al. Nonselective loss of contrast sensitivity in visual system testing in early type I diabetes. Diabetes Care. 1992;15:620-625.
116. Ismail GM, Whitaker D. Early detection of changes in visual function in diabetes mellitus. Ophthalmic Physiol Opt. 1998;18:3-12.
117. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan D, Hirose T. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2001;239:643-648.